💸 The Tape

On June 3, 2026, Trulieve filed an 8-K with the SEC disclosing what the company calls a "Deconsolidation Transaction" — a carefully engineered separation of its medical cannabis business from its mixed-use (adult-use) cannabis operations designed to accomplish one specific objective: qualify for listing on the New York Stock Exchange.

The structure is elegant, aggressive, and built with a very deliberate off-ramp. Here's how it works — and why it matters.

The Transaction Architecture

Trulieve carved its adult-use cannabis operations into Harvest Enterprises, LLC ("Harvest"), a subsidiary that previously held the company's mixed-use business. An outside investor — Whitley Holding 05192026, LLC (the "Harvest Investor") — acquired Class A voting units representing a 10% economic ownership interest in Harvest for approximately $14.8 million.

Trulieve's subsidiary retains Non-Voting Units in Harvest — units that carry no voting rights, no dividend rights, no ability to direct business operations, and no rights upon dissolution. These units are only convertible into Common Units (standard equity) after the "Stock Exchange Permissibility Date" — defined as the date the NYSE permits listing of companies that consolidate entities engaged in non-medical cannabis in the United States.

The Harvest Investor appointed two of three board members (Frank Whitley and Rudy Rowe), while Trulieve appointed CEO Kim Rivers as the third. But critically, Trulieve's representative holds no controlling authority — the Harvest Board is controlled by the outside investor.

The result: under U.S. GAAP, Trulieve no longer consolidates Harvest's financial results. The adult-use business is deconsolidated. What remains on Trulieve's books is a pure medical cannabis company — exactly the kind of entity that a major U.S. exchange can list under the current Schedule III framework, which applies only to state-licensed medical marijuana.

The Margin Transformation

The pro forma financial statements filed alongside the 8-K reveal the dramatic impact of stripping out the mixed-use business.

On a reported basis, Trulieve generated $286.8 million in Q1 2026 revenue with gross profit of $170.1 million — a 59.3% gross margin. After deconsolidating Harvest's $72.7 million in revenue and $32.2 million in gross profit, the remaining medical business shows pro forma revenue of $214 million with gross profit of $137.9 million — a 64.4% gross margin.

That's a 510 basis point improvement in gross margin simply from removing the lower-margin adult-use operations. Medical cannabis, with its established patient bases, less promotional pricing dynamics, and stable demand patterns, has always been the higher-margin business. The deconsolidation makes that visible for the first time.

On the bottom line, pro forma net income attributable to common shareholders improves to $5.97 million from $2.41 million as reported — driven by the removal of Harvest's operating losses, reduced SG&A, and lower depreciation and amortization. The medical-only Trulieve also carries a significantly lighter tax burden, with the uncertain tax position liability (the 280E reserve) dropping from $696.4 million to $538.3 million — reflecting the elimination of 280E exposure on the deconsolidated adult-use operations.

The Built-In Reconsolidation

Here's where the structure gets truly clever. The Non-Voting Units that Trulieve's subsidiary holds in Harvest are automatically convertible into Common Units once the NYSE permits listing of companies with adult-use cannabis operations. That conversion is not optional — it's built into the LLC Agreement.

If the DEA's administrative hearing beginning June 29 results in broader rescheduling of all marijuana to Schedule III — or if the NYSE independently updates its listing standards to accommodate adult-use cannabis companies — the Stock Exchange Permissibility Date triggers, Trulieve's Non-Voting Units convert to Common Units, and the company reconsolidates Harvest's financials back onto its books.

At that point, Trulieve would be listed on the NYSE as a fully integrated medical and adult-use operator — with all the institutional investor access, index inclusion eligibility, and cost-of-capital advantages that come with a major exchange listing. The Harvest Investor's Voting Units would represent no less than 10% of total outstanding units post-conversion, meaning Trulieve's subsidiary would own up to 90% of the reconsolidated entity.

The deconsolidation is designed to be temporary. It's a bridge — a legal and accounting mechanism that allows Trulieve to access the NYSE now while preserving its right to reunify the business when regulations permit.

The Protection Agreement

To ensure the adult-use business isn't mismanaged during the separation, the Protection Agreement establishes covenants that preserve the value of Trulieve's Non-Voting Units. While it explicitly does not give Trulieve the ability to direct Harvest's operations (which would defeat the deconsolidation), it creates guardrails designed to prevent value destruction.

Trulieve also entered into a Management Services Agreement under which a subsidiary will provide consulting, advisory, and administrative services to Harvest for cost plus a 5% margin, subject to a cap. Either party can terminate the MSA with 90 days' notice. This arrangement keeps Trulieve's operational expertise flowing into the adult-use business without creating the control relationship that would force reconsolidation.

What This Means for the Industry

Trulieve's deconsolidation is the most explicit signal yet that the largest U.S. cannabis operators are not waiting for perfect regulatory clarity to pursue major exchange listings. They're engineering structures that work within the current framework — Schedule III covers medical, so build a medical-only entity for listing purposes — while maintaining full optionality for reconsolidation when the framework expands.

This is the same strategic logic behind Curaleaf's 1-for-3 reverse stock split, Verano's 1-for-5 reverse split, and the wave of redomiciliation announcements from Trulieve (to Delaware), Jushi (to Nevada), and others. The industry is collectively preparing for uplisting — and Trulieve just took the most aggressive step of any operator to date.

The $14.8 million that Whitley Holding paid for 10% of Harvest implies an enterprise value of approximately $148 million for the adult-use business — a fraction of what those operations would command in a normalized market. The Harvest Investor is essentially acquiring a discounted call option on the eventual reunification of Trulieve's full business under a major exchange listing.

The Bottom Line

Trulieve didn't just file an 8-K. It filed a blueprint for how the U.S. cannabis industry transitions from the CSE and OTC markets to the NYSE and Nasdaq.

The medical-only entity that emerges from this transaction generates $214 million in quarterly pro forma revenue at a 64% gross margin with positive net income and a dramatically cleaner balance sheet. It's a company that, on paper, looks like a specialty pharmaceutical business — which is exactly the point.

If the June 29 hearing produces broader rescheduling, the structure unwinds, the business reconsolidates, and Trulieve becomes a fully integrated operator listed on the most prestigious stock exchange in the world. If it doesn't, Trulieve still has a NYSE-ready medical cannabis company generating substantial revenue and profitability.

It's a heads-I-win, tails-I-still-win structure. And the rest of the industry is watching very carefully.

📈 Dog Walkers

$ROMJ.TSX ( 0.0% ) Wins Brand of the Year + Best Flower Awards

Rubicon Organics keeps collecting hardware — and in the premium cannabis segment, awards aren't just vanity metrics. They're shelf-space leverage.

The company announced multiple wins at the 2026 Grow Up Industry Awards, including Brand of the Year for 1964 Supply Co.™ and Best Dry Flower for Simply Bare™ Organics BC Organic Fruit Loopz. It's the second consecutive year Rubicon has earned recognition at the national awards — a streak that reinforces the company's position as Canada's No. 1 selling premium licensed producer based on Hifyre retail market share data spanning January 2025 through March 2026.

The Grow Up Awards, held annually in Toronto as part of the Grow Up Conference & Expo, have served as a national benchmark for cannabis excellence since 2019, recognizing leaders across cultivation, product development, and commercial performance. In a category where consumer trust and budtender recommendations drive purchasing decisions, consistent recognition at this level translates directly into competitive advantage.

CEO Margaret Brodie framed the wins as validation of the broader platform: "Rubicon is building a house of leading premium brands, leveraging our deep genetic library and craft cultivation methods to consistently deliver the experiences consumers and budtenders expect from our products."

That brand portfolio — 1964 Supply Co.™, Simply Bare™ Organics, and Wildflower — spans the premium and super-premium tiers of the Canadian market, each targeting distinct consumer segments with differentiated positioning. 1964 Supply Co. in particular has been on a tear, recently entering the UK medical cannabis market through a distribution partnership with 4C LABS and winning Brand of the Year at the KIND Awards for two consecutive years prior to this latest recognition.

For Rubicon, the awards reinforce a simple thesis: in a commoditizing cannabis market, premium brands built on genetic depth, organic cultivation, and consistent quality command both consumer loyalty and category leadership.

$RWBYF ( 0.0% ) Is Still Alive!?

Red White & Bloom is tightening its grip on the Ayurcann acquisition — and it's doing it by becoming the bankroller keeping the lights on.

The company's subsidiary Emblem Cannabis Corporation has completed the assignment and assumption of the DIP (debtor-in-possession) lending facility previously provided by Auxly Cannabis Group to Ayurcann, which has been operating under CCAA creditor protection since January 2026. Emblem paid Auxly approximately C$1.6 million to take over the full outstanding indebtedness, acquiring all related loan documents, security interests, and the court-ordered DIP Lender's Charge in the process.

Simultaneously, Emblem entered into an amended and restated DIP commitment letter with the Ayurcann entities, committing up to C$3 million in non-revolving financing at 12% annual interest to fund Ayurcann's working capital, restructuring expenses, and professional fees through the remainder of the CCAA proceedings.

The move is strategically deliberate. By stepping into the DIP lender role, Emblem ensures that the business it intends to acquire continues operating smoothly through closing — while also securing the senior secured position in Ayurcann's capital stack. If anything goes sideways before the deal closes, Emblem sits at the front of the creditor line.

The acquisition itself — announced in April 2026 after Emblem was selected as the winning bidder in the court-supervised sale process — gives RWB access to Ayurcann's processing and manufacturing platform in Pickering, Ontario, along with its brand portfolio (Fuego, Xplor, Happy & Stoned), over 90 tracked SKUs, distribution across eight provinces, and retail presence in approximately 2,500 locations.

Closing is anticipated on or about June 5, 2026, and no later than June 30, subject to court approval and customary conditions.

For RWB, taking over the DIP facility isn't just financial housekeeping — it's ensuring the asset arrives intact on closing day.

🗞️ The News

📺 Trade To Black

The Uplisting Blueprint Is Taking Shape | TTB Presented by Flowhub

• Trulieve's Uplisting Blueprint: Trulieve's deconsolidation of its adult-use business from its medical operations creates the first real roadmap for U.S. cannabis operators seeking NYSE eligibility under the current Schedule III framework.

• Industry Signal: The structure raises a critical question — whether other major MSOs will follow Trulieve's lead in separating medical and adult-use operations to pursue senior exchange listings while broader rescheduling plays out.

• NewLake CEO Weighs In: Anthony Coniglio of NewLake Capital Partners discusses growing institutional interest in cannabis, the wave of reverse stock splits across the sector, and whether meaningful Wall Street participation is finally approaching.

• Capital Markets Inflection: Between Trulieve's corporate restructuring, Curaleaf and Verano's reverse splits, and increasing institutional engagement, the cannabis sector may be entering the most significant capital markets transition in its history.